May 14, 2013
$PVCT CEO Letter: PV-10 Compassionate Use Data To Come
When I heard 75% of compassionate use program (CUP) patients were cancer-free (but without any specifics regarding longevity), I wanted context/more information with which to compare this PV-10 success rate. I found some expanded access program data for ipilimumab:
Whether adjusting for patients receiving ipilimumab who were lost to follow-up or not (>20% or more), a "rough" comparison with PV-10 (75%) is notable to say the least.